The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Clinical outcomes of camrelizumab + rivoceranib vs sorafenib (CARES-310) as first-line treatment for patients with unresectable hepatocellular carcinoma (uHCC) of non-viral and viral etiology.
 
Rachna Shroff
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Genentech; Jazz Pharmaceuticals; Merck; Merus
Research Funding - Actuate Therapeutics; Bristol-Myers Squibb; Compass Therapeutics; Exelixis; Faeth Therapeutics; Fujifilm; Immunovaccine; Lisata; Loxo/Lilly; Merck; NGM Biopharmaceuticals; Novocure; Nucana; Rafael Pharmaceuticals; Seagen
 
Wei Shi
Employment - Jiangsu Hengrui Pharmaceuticals
Stock and Other Ownership Interests - Jiangsu Hengrui Pharmaceuticals
 
Xiuzhi Wu
Employment - Jiangsu Hengrui Pharmaceuticals
Stock and Other Ownership Interests - Jiangsu Hengrui Pharmaceuticals
 
Xianzhang Meng
Employment - Elevar Therapeutics
Stock and Other Ownership Interests - Elevar Therapeutics
 
Melissa Maj
Employment - Elevar Therapeutics
Stock and Other Ownership Interests - Elevar Therapeutics
 
Kristin Ryan
Employment - Elevar Therapeutics
Stock and Other Ownership Interests - Elevar Therapeutics
 
Chris Galloway
Employment - Elevar Therapeutics
Stock and Other Ownership Interests - Elevar Therapeutics
 
Laura Alexander
Employment - Elevar Therapeutics
Stock and Other Ownership Interests - Elevar Therapeutics